Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

FDA Grants Genentech’s Perjeta Regimen Priority Review

07:57 EDT 2 Jul 2013 | PharmPro

Genentech, a member of the Roche Group, today announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) for the use of a Perjeta® (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with...

Original Article: FDA Grants Genentech’s Perjeta Regimen Priority Review

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Genentech’s Perjeta Regimen Priority Review"

Search BioPortfolio: